Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4491001 | 0.75 | GPR119 (0.44) | GPR119CYP3A4 | |
| SCHEMBL3930505 | 0.74 | GPR119 (0.45) | GPR119CYP3A4 | |
| SCHEMBL2785258 | 0.74 | GPR119 (0.56) | GPR119CYP3A4 | |
| SCHEMBL15196391 | 0.71 | GPR119 (0.47) | GPR119CYP3A4 | |
| SCHEMBL4495992 | 0.71 | NPC1 (0.36) | — | |
| SCHEMBL30871243 | 0.69 | CA1 (0.44) | GPR119 | |
| SCHEMBL10120559 | 0.68 | GPR119 (0.51) | GPR119CYP3A4 | |
| SCHEMBL14875298 | 0.67 | CA1 (0.49) | LRRK2 | |
| SCHEMBL4497189 | 0.67 | GALR3 (0.38) | PKMALDH1A1MAPT | |
| SCHEMBL10134288 | 0.67 | GPR119 (0.53) | GPR119TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822480-B2 | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822480-B2 | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators | MERCK SHARP & DOHME CORP. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | SCHERING CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166165-A1 | BICYCLIC HETEROCYCLE DERIVATIVES AND USE THEREOF AS GPR119 MODULATORS | GPR119, GPR88, GCGR | PKM 1950/4885GPR119 1/4885ALDH1A1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.